MX2020006942A - Dominios ck y ch1 modificados. - Google Patents
Dominios ck y ch1 modificados.Info
- Publication number
- MX2020006942A MX2020006942A MX2020006942A MX2020006942A MX2020006942A MX 2020006942 A MX2020006942 A MX 2020006942A MX 2020006942 A MX2020006942 A MX 2020006942A MX 2020006942 A MX2020006942 A MX 2020006942A MX 2020006942 A MX2020006942 A MX 2020006942A
- Authority
- MX
- Mexico
- Prior art keywords
- cîo
- domains
- modified
- pairing
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Abstract
Se proporcionan anticuerpos y fragmentos de unión a antígeno con los dominios C? y CH1 modificados que aún permiten el emparejamiento de los dominios C? y CH1, pero que tienen emparejamiento reducido con los dominios C? y CH1 de tipo silvestre sin las modificaciones. Dichas modificaciones pueden ser particularmente útiles para preparar anticuerpos biespecíficos con dos pares diferentes de dominios C? y CH1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018072564 | 2018-01-15 | ||
PCT/CN2019/071740 WO2019137552A1 (en) | 2018-01-15 | 2019-01-15 | MODIFIED Cκ AND CH1 DOMAINS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006942A true MX2020006942A (es) | 2020-09-14 |
Family
ID=67219407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006942A MX2020006942A (es) | 2018-01-15 | 2019-01-15 | Dominios ck y ch1 modificados. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190389972A1 (es) |
EP (1) | EP3577141A4 (es) |
JP (1) | JP6996825B2 (es) |
KR (1) | KR102471868B1 (es) |
CN (1) | CN110573531B (es) |
AU (2) | AU2019203917B2 (es) |
BR (1) | BR112020009414A2 (es) |
CA (1) | CA3084398A1 (es) |
EA (1) | EA202091053A1 (es) |
IL (1) | IL275943B (es) |
MX (1) | MX2020006942A (es) |
SG (1) | SG11202005009RA (es) |
WO (1) | WO2019137552A1 (es) |
ZA (1) | ZA202002567B (es) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007147901A1 (en) * | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
JP6506024B2 (ja) * | 2012-11-05 | 2019-04-24 | 全薬工業株式会社 | 抗体又は抗体組成物の製造方法 |
EP2970435B1 (en) * | 2013-03-15 | 2020-08-12 | Eli Lilly and Company | Methods for producing fabs and bi-specific antibodies |
UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP3143043B1 (en) * | 2014-05-16 | 2022-12-14 | Pfizer Inc. | Bispecific antibodies with engineered ch1-cl interfaces |
DK3107938T3 (da) * | 2014-05-28 | 2022-07-11 | Zymeworks Inc | Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf |
KR102588377B1 (ko) * | 2014-11-14 | 2023-10-12 | 에프. 호프만-라 로슈 아게 | Tnf 계열 리간드 삼량체를 포함하는 항원 결합 분자 |
EP3150636A1 (en) * | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
CN108290958B (zh) * | 2015-10-02 | 2021-12-28 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
CN115920030A (zh) * | 2015-12-09 | 2023-04-07 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
AU2016381605A1 (en) * | 2015-12-28 | 2018-07-12 | Massachusetts Institute Of Technology | Bispecific antibodies having constant region mutations and uses therefor |
HUE057657T2 (hu) * | 2016-03-25 | 2022-06-28 | Biomunex Pharmaceuticals | CD38-hoz és PD-L1-hez kötõdõ molekulák |
-
2019
- 2019-01-15 EP EP19730101.3A patent/EP3577141A4/en active Pending
- 2019-01-15 SG SG11202005009RA patent/SG11202005009RA/en unknown
- 2019-01-15 AU AU2019203917A patent/AU2019203917B2/en active Active
- 2019-01-15 CA CA3084398A patent/CA3084398A1/en active Pending
- 2019-01-15 JP JP2020524871A patent/JP6996825B2/ja active Active
- 2019-01-15 WO PCT/CN2019/071740 patent/WO2019137552A1/en unknown
- 2019-01-15 EA EA202091053A patent/EA202091053A1/ru unknown
- 2019-01-15 MX MX2020006942A patent/MX2020006942A/es unknown
- 2019-01-15 US US16/489,970 patent/US20190389972A1/en active Pending
- 2019-01-15 CN CN201980001527.7A patent/CN110573531B/zh active Active
- 2019-01-15 BR BR112020009414-5A patent/BR112020009414A2/pt unknown
- 2019-01-15 KR KR1020197022000A patent/KR102471868B1/ko active IP Right Grant
-
2020
- 2020-05-08 ZA ZA2020/02567A patent/ZA202002567B/en unknown
- 2020-05-08 AU AU2020203065A patent/AU2020203065B2/en not_active Expired - Fee Related
- 2020-07-09 IL IL275943A patent/IL275943B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200059186A (ko) | 2020-05-28 |
KR102471868B1 (ko) | 2022-11-30 |
EA202091053A1 (ru) | 2020-12-03 |
CN110573531B (zh) | 2021-04-02 |
EP3577141A1 (en) | 2019-12-11 |
AU2019203917B2 (en) | 2020-04-02 |
CA3084398A1 (en) | 2019-07-18 |
IL275943A (en) | 2020-08-31 |
JP6996825B2 (ja) | 2022-01-17 |
AU2019203917A1 (en) | 2019-08-01 |
EP3577141A4 (en) | 2021-02-17 |
IL275943B (en) | 2022-06-01 |
AU2020203065B2 (en) | 2023-04-06 |
SG11202005009RA (en) | 2020-06-29 |
AU2020203065A1 (en) | 2020-05-28 |
US20190389972A1 (en) | 2019-12-26 |
CN110573531A (zh) | 2019-12-13 |
BR112020009414A2 (pt) | 2020-11-03 |
ZA202002567B (en) | 2021-04-28 |
WO2019137552A1 (en) | 2019-07-18 |
JP2021506747A (ja) | 2021-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502282A1 (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
PH12019502283A1 (en) | Anti-lag3 antibodies | |
MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
JOP20180042A1 (ar) | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام | |
JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
NZ732628A (en) | Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof | |
NI201400019A (es) | Anticuerpo anti-alfabetatcr | |
PH12018500710A1 (en) | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use | |
JOP20190246A1 (ar) | جسم مضاد أحادي النسيلة لـ pd-l1 | |
EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
MX2019011585A (es) | Anticuerpos miltiespecificos estables. | |
GEP20217311B (en) | High affinity and aggregatively stable antibodies on basis of variable domains vl and derivative vhh | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
WO2020128870A3 (en) | Methods of producing heterodimeric antibodies | |
PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
MX2020011614A (es) | Anticuerpos con perfiles de glicanos modulados. | |
MX2020006942A (es) | Dominios ck y ch1 modificados. | |
PH12021550991A1 (en) | Monoclonal antibody that specifically binds to cd20 | |
PH12020550218A1 (en) | MONOCLONAL ANTIBODY TO IL-5Ra | |
MX2021007369A (es) | Combinacion farmaceutica de anticuerpos anti ceacam6 y tim3. | |
IL280745A (en) | Anti-FC epsilon-R1 alpha (FCER1A) antibodies, bispecific antigen-binding molecules that bind FCER1A and CD3, and uses thereof | |
SG11202103275YA (en) | Downstream processing of bispecific antibody constructs |